Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

WEXFORD, Pa., Jan. 22, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it has regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's decision of September 17, 2024."We thank the Nasdaq Hearings Panel for approving our request," said Coeptis' Chief Executive O ...